For the third quarter, GoodRx booked revenue of just over $195.3 million, representing growth of 8% over the same period of 2023. Non-GAAP (adjusted) net income was $31.9 million, or $0.08 per share, ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

The average one-year price target for GoodRx Holdings (NasdaqGS:GDRX) has been revised to $2.87 / share. This is a decrease ...

GoodRx, which specializes in prescription and telehealth services, saw its revenue rise by almost 3% year-over-year to just under $203 million. Non-GAAP (adjusted) net income also advanced, increasing ...

On this episode of Stock Movers: - Novo Nordisk (NVO) shares rise after news that it's slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx ...

I'm reiterating my Buy rating on GoodRx, as its valuation is compelling and the business is showing signs of stabilization under new leadership. GoodRx's recurring revenue base, expanding pharma ...

GoodRx offers compelling value after a ~50% stock decline over the past 12 months, trading at just 6.1x FY25 adjusted EBITDA despite recent execution challenges. A new Novo Nordisk partnership for ...

The healthcare services specialist unveiled its first set of quarterly results for this year. It beat on both the top and bottom lines, and slightly increased its guidance for a profitability metric.